OTC: IMVIQ - IMV Inc.

六个月盈利: 0%
股息率: 0.00%
部门: Healthcare

促销时间表 IMV Inc.


关于公司 IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer.

更多详情
It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.imv-inc.com
Цена ао 0.0001
每日价格变化: 0% (0.0001)
每周价格变化: 0% (0.0001)
每月价格变化: 0% (0.0001)
3个月内价格变化: 0% (0.0001)
六个月内的价格变化: 0% (0.0001)
每年价格变化: 0% (0.0001)
3年内价格变化: -100% (15)
5年内价格变化: -100% (21.8)
年初以来价格变化: 0% (0.0001)

低估

姓名 意义 年级
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
全部的: 2.5

效率

姓名 意义 年级
ROA, % 0 0
ROE, % 0 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA 0 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 154.97 10
盈利能力 EPS, % 873.03 10
全部的: 8



导师 职称 支付 出生年份
Mr. Andrew Hall M.Sc. CEO & Director 680.6k
Ms. Brittany Davison C.A., CPA Chief Accounting Officer, Corporate Secretary & Director 207.9k 1990 (35 年)
Delphine Davan Senior Director of Communications & Investor Relations N/A
Mr. Stephan Fiset M.B.A., M.Sc. Vice President of Clinical Research N/A
Dr. Jeremy R. Graff Ph.D. Chief Scientific Officer 1971 (54 年)

地址: Canada, Dartmouth. NS BB C, 130 Eileen Stubbs Avenue - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.imv-inc.com